ALK and non-small cell lung carcinoma: Targeted therapy with TKIs, including crizotinib (first-generation), alectinib, ceritinib, ansatinib, brigatinib (second-generation), and loratinib (third-generation), has been developed for ALK-rearranged NSCLC (75–77).